Evidence map›Paper›PMID 36059986›Full record

ArticleFrontiers in pharmacology2022

Ruxolitinib inhibits cytokine production by human lung macrophages without impairing phagocytic ability.

Nikola Mantov, Mathilde Zrounba, Marion Brollo, S Grassin-Delyle, Matthieu Glorion, Mélanie David, Emmanuel Naline, Philippe Devillier, Hélène Salvator

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Nikola MantovLaboratory of Research in Respiratory Pharmacology-Virologie et Immunologie Moleculaire (VIM) Suresnes, V2I-UMR-0892 Paris Saclay University, Suresnes, France.
Mathilde ZrounbaLaboratory of Research in Respiratory Pharmacology-Virologie et Immunologie Moleculaire (VIM) Suresnes, V2I-UMR-0892 Paris Saclay University, Suresnes, France.
Marion BrolloLaboratory of Research in Respiratory Pharmacology-Virologie et Immunologie Moleculaire (VIM) Suresnes, V2I-UMR-0892 Paris Saclay University, Suresnes, France.
S Grassin-DelyleRespiratory Diseases Department, Foch Hospital, Suresnes, France.
Matthieu GlorionLaboratory of Research in Respiratory Pharmacology-Virologie et Immunologie Moleculaire (VIM) Suresnes, V2I-UMR-0892 Paris Saclay University, Suresnes, France.
Mélanie DavidLaboratory of Research in Respiratory Pharmacology-Virologie et Immunologie Moleculaire (VIM) Suresnes, V2I-UMR-0892 Paris Saclay University, Suresnes, France.
Emmanuel NalineLaboratory of Research in Respiratory Pharmacology-Virologie et Immunologie Moleculaire (VIM) Suresnes, V2I-UMR-0892 Paris Saclay University, Suresnes, France.
Philippe DevillierLaboratory of Research in Respiratory Pharmacology-Virologie et Immunologie Moleculaire (VIM) Suresnes, V2I-UMR-0892 Paris Saclay University, Suresnes, France.
Hélène SalvatorLaboratory of Research in Respiratory Pharmacology-Virologie et Immunologie Moleculaire (VIM) Suresnes, V2I-UMR-0892 Paris Saclay University, Suresnes, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

budenosidecytokinehuman macrophagesJanus kinase (2)-signal transducers and activators of transcription [JAK2-STAT5]ruxolitinib

Identifiers

PMID36059986
PMCPMC9437255

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.